Autologous transplant in multiple myeloma with an augmented conditioning protocol

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Autologous stem cell transplant (auto-SCT) is a key treatment for multiple myeloma.
• Optimizing conditioning regimens is crucial for improving patient outcomes and reducing toxicity.

Purpose of the Study:

• To compare the tolerability and efficacy of two distinct conditioning regimens prior to auto-SCT in multiple myeloma patients.
• To evaluate the impact of sequential etoposide, thiotepa, and melphalan versus melphalan alone on survival and time to progression.

Main Methods:

• A retrospective comparison of two consecutive patient groups undergoing auto-SCT for multiple myeloma.
• Protocol 1: Etoposide, thiotepa, and melphalan (n=29). Protocol 2: Melphalan alone (n=34).
• Assessment of toxicity (febrile days, parenteral nutrition) and clinical outcomes (survival, time to progression).

Main Results:

• Protocol 1 demonstrated higher toxicity, evidenced by more febrile days and increased need for parenteral nutrition.
• Patients receiving Protocol 1 had a significantly longer time to progression (44 months vs. 17 months, p=0.033).
• Median survival was not reached with Protocol 1, whereas it was 59 months with Protocol 2 (p=0.039), suggesting a potential survival benefit with the combined regimen.

Conclusions:

• Sequential conditioning with etoposide, thiotepa, and melphalan appears to offer a survival and progression-free survival benefit for multiple myeloma patients undergoing auto-SCT.
• While associated with slightly increased toxicity, this regimen may be a valuable option for selected patients.
• Further investigation in larger cohorts is warranted to confirm these findings.